DBVT · available-data snapshot
DBV Technologies S.A. (DBVT): Available-Data Snapshot
TickerWorth does not publish a DCF fair value for DBV Technologies S.A. (DBVT); the reason is set out below. What its filings and market data do show is below. The snapshot also sets out its trading multiples against 5 peers. Snapshot as of Oct 19, 2026.
Model by Miraaj Patel · generated from public market data · Updated Oct 19, 2026 · How these pages are made
Why is there no fair value for DBVT?
We do not publish a fair value for DBV Technologies S.A.. What we can say from its filings and market data is below.
What is DBVT's TickerWorth Score?
Scores lower than almost every company we compare it with
Compared with Healthcare companies in US
Its strongest point: strong balance sheet. Its weakest: trades above our estimate of what it's worth.
- Value · 22 of 100
Cheaper than 22% of Healthcare companies in US
- Price vs worth · 0 of 100
- Quality · 36 of 100
More profitable than 36% of Healthcare companies in US
- Financial health · 56 of 100
Financially stronger than 56% of Healthcare companies in US
- Growth · 3 of 100
Growing faster than 3% of Healthcare companies in US
- Momentum · 3 of 100
Outperformed 3% of Healthcare companies in US over the past year
Confidence: Medium confidence · Scored
Get the Undervalued Company of the Week.
- Price
- $8.97
- Market cap
- $563,
751, 040 - 52-week high
- $26.18
- 52-week low
- $8.63
- Currency
- USD
- Exchange
- NasdaqCM
Snapshot of Oct 19, 2026, quote time not published · Prices are delayed.
What we can say
We don't publish a discounted-cash-flow fair value for DBV Technologies S.A. (DBVT) because the free data sources we rely on don't expose the multi-year financials a DCF needs — common for small or thinly-covered listings. Rather than invent numbers, this page shows an honest snapshot of what the public data does support: the current price and size, any relative valuation multiples that exist, a book-value view, and a price-based read. Treat it as a descriptive starting point, not a valuation and not investment advice.
Read the full reasoning
On the numbers we do have, DBVT trades at a recent price of $8.97, a market capitalisation of about $563,751,040, sitting 2% of the way up its 52-week range ($8.63–$26.18), on the NasdaqCM.
The standard alternative to a DCF is relative valuation — comparing DBVT's trading multiples against a sector benchmark. Here that gives P/B of 3.3× (cheaper than the peer median of 7.8×); P/S of 111.9× (richer than the peer median of 6.2×). A cheaper multiple than peers can flag a discount or a market that expects weaker growth; it is a comparison, not a recommendation.
The asset, or book-value, lens is the classic tool for asset-heavy businesses and financials. DBVT shows a price-to-book (P/B) of 3.31 and book value of $2.71 per share. Price-to-book compares the market price to the accounting net-asset value per share; below 1.0 can mean a discount to net assets or that the market is pricing in trouble — descriptive either way, never a buy signal on its own.
Finally, a price-based read — explicitly not a valuation. DBVT is in a down-trend (price below both its 50- and 200-day averages), trading -65.7% from its 52-week high. Over the past year the stock is -44.5%. Moving-average trend and 52-week position describe where the stock has traded; they say nothing about what it is worth.
DBVT vs peers
Sector benchmark (bellwethers, not direct competitors).
| Multiple | DBVT | Peer median | Read |
|---|---|---|---|
| P/B | 3.3× | 7.8× | cheaper than |
| P/S | 111.9× | 6.2× | richer than |
What does DBV Technologies S.A. do?
What does it do?
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. It operates in the Biotechnology industry (Healthcare sector), headquartered in France. The company employs roughly 170 people.
How does it make money?
The business turns $6M in annual revenue into profit. Out of every $100 of sales, about $0 is left as operating profit (operating margin of -7228.6%), after a 100% gross margin on the products/services it sells. After all costs, taxes and interest, 0.0% of revenue becomes bottom-line net profit.
Is it financially healthy?
Financially it looks mixed: carries heavy debt (4.8× equity), comfortably covers its short-term bills (3.7× current ratio), and is currently lossmaking.
Who at DBVT filed insider trades?
| Date | Insider | Relationship | What happened | Value | Filing |
|---|---|---|---|---|---|
| Mohideen Pharis | Chief Medical Officer | Open-market sale | $1,252.80 | Form 4 for Mohideen Pharis (opens sec.gov in a new tab) | |
| Mohideen Pharis | Chief Medical Officer | Open-market sale | $2,595.24 | Form 4 for Mohideen Pharis (opens sec.gov in a new tab) | |
| EPIC Bpifrance | — | Open-market sale | $5,413,911.57 | Form 4 for EPIC Bpifrance (opens sec.gov in a new tab) | |
| EPIC Bpifrance | — | Open-market sale | $9,859,031.60 | Form 4 for EPIC Bpifrance (opens sec.gov in a new tab) | |
| EPIC Bpifrance | — | Open-market sale | $211,200.00 | Form 4 for EPIC Bpifrance (opens sec.gov in a new tab) | |
| Mohideen Pharis | Chief Medical Officer | Open-market sale | $4,498.48 | Form 4 for Mohideen Pharis (opens sec.gov in a new tab) |
A disclosure, not a signal to trade. Source: SEC EDGAR (Form 4). Older filings and the 90-day buying-and-selling read are part of Pro. See plans
Companies we do put a number on
Not investment advice. TickerWorth Score is a model output.
A descriptive, available-data snapshot and relative comparison — NOT a DCF, NOT a price target, and NOT investment advice. TickerWorth is not a licensed investment adviser, and these figures are estimates from public market data that can be wrong, stale or incomplete.